Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Obinutuzumab
Related studies linked through entity extraction aliases.
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- SUSPENDED
- Phase
- PHASE1
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)
- Status
- RECRUITING
- Phase
- PHASE3
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
- Status
- RECRUITING
- Phase
- PHASE2
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Status
- RECRUITING
- Phase
- PHASE3
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
- Status
- RECRUITING
- Phase
- PHASE2